ASCO26: Sara Tolaney, MD, MPH, ASCENT-04 - Summary - MDSpire

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

Share

Objective:

To present a subgroup analysis of the ASCENT-04 study based on biomarkers.

Approach:
  • Study Design: Subgroup analysis of the ASCENT-04 study focusing on the efficacy of sacituzumab govitecan plus pembro compared to standard therapy.
Key Findings:
  • Patients receiving sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to those on standard therapy.
Interpretation:

Strategies to improve adoption of ePRO-based symptom management may be warranted.

Conclusion:

Original Source(s)

ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

  • July 1, 2026

Related Content

Molecular changes during AT/RT progression associated with epithelial–mesenchymal transition and extracellular matrix changes

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

Bystander and abscopal effects of boron neutron capture therapy: radiobiological mechanisms and immunotherapeutic strategies